EU Biotechs Look To Standardize Biosimilar Labeling For Safety Reasons
This article was originally published in The Pink Sheet Daily
Executive Summary
The EU biotech industry is making a concerted effort to standardize biosimilars product labeling across Europe, but there are fears this might hamper uptake and impact negatively on pharmaceutical budgets.